Prevalence of fabry's disease within hemodialysis patients in Spain

Clinical Nephrology

Volumn 81, Issue 2, 2014, Pages 112-120

  Herrera, Julio ^a   Miranda, Clara Sa ^b  

^a Hospital Universitario Central   (Spain)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

galactosidase A activity; Dried blood spot; Fabry's disease prevalence; Hemodialysis; Kidney dysfunction

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; AGED; ARTICLE; D109G GENE; DRIED BLOOD SPOT TESTING; ENZYME ASSAY; FABRY DISEASE; FEMALE; GENE; GENE MUTATION; GENOTYPE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; SPAIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; DRIED BLOOD SPOT TESTING; FABRY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; RENAL DIALYSIS; RISK FACTORS; SPAIN;

EID: 84893180941     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108053     Document Type: Article

References (48)

1. Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000; 284: 2771-2775. CrossRef PubMed
2. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: FD. The metabolic and molecular basis of inherited disease. McGraw-Hill, USAScriver CR, Beaud Sly WS, Valle D, Kinzler KE, Vogelstein B (eds.). New York: McGraw-Hill; 2001. p. 3733-3774.
3. Navarro C, Teijeira S, Domínguez C, Fernández JM, Rivas E, Fachal C, Barrera S, Rodriguez C, Iranzo P. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. Acta Neuropathol. 2006; 111:178-185. CrossRef PubMed
4. Hauser AC, Lorenz M, Sunder-Plassmann G. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. J Intern Med. 2004; 255: 629-636. CrossRef PubMed
5. Sessa A, Meroni M, Battini G, Righetti M, Mignani R. Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease. Semin Nephrol. 2004; 24: 532-536. CrossRef PubMed
6. Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, Roscher AA, Muntau AC. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl. 2006; 95: 30-38. CrossRef PubMed
7. Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol. 2002; 13 (Suppl 2): S130-S133. PubMed
8. Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG. Nephropathy in Fabry disease: the importance of early diagnosis and testing in highrisk populations. Nephrol Dial Transplant. 2009; 24: 1736-1743. CrossRef PubMed
9. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet. 1996; 33: 682-688. CrossRef PubMed
10. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999; 281: 249-254. CrossRef PubMed
11. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006; 79: 31-40. CrossRef PubMed
12. Spada M, Pagliardini S. Screening for Fabry disease in end-stage nephropahies. J Inherit Metab Dis. 2002; 25 (Supp 1): 113.
13. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 2003; 64: 801-807. CrossRef PubMed
14. Linthorst GE, Hollak CEM, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW. a- Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant. 2003; 18: 1581-1584. CrossRef PubMed
15. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, et al. Results of a nationwide screening for Anderson- Fabry disease among dialysis patients. J Am Soc Nephrol. 2004; 15: 1323-1329. CrossRef PubMed
16. Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G, Unwin R, Jaeger P. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract. 2005; 101: c33-c38. CrossRef PubMed
17. Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005; 64: 281-287. CrossRef PubMed
18. Merta M, Reiterova J, Ledvinova J, Poupetová H, Dobrovolny R, Rysavá R, Maixnerová D, Bultas J, Motán J, Slivkova J, Sobotova D, Smrzova J, Tesar V. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant. 2007; 22: 179-186. CrossRef PubMed
19. Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, Forascepi R, Macias J, del Pino MD, Prados MD, de Alegria PR, Torres G, Vidau P, Sá-Miranda MC. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010; 11: 19. Cross- Ref PubMed
20. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta. 1981; 112: 247-251. CrossRef PubMed
21. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003; 138: 338-346. CrossRef PubMed
22. European Medicines Agency (EMEA). Note for guidance on Good Clinical Practice CPMP/ ICH/135/95, July 2002.
23. Shabbeer J, Robinson M, Desnick RJ. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum Mutat. 2005;25:299-305. CrossRef PubMed
24. Claverie Martín F, Ramos Trujillo E, González Paredes F. J. Técnicas para el diagnóstico molecular de enfermedades hereditarias. Bol Pediatr. 2008; 48: 235-241.
25. Arrieta J, Gutiérrez Ávila G, Moreno Alía I, Sierra Yébenes T, Estébanez C, Olmos Linares AM, González R, Fernández Renedo C, Arias M, Cotorruelo J, de Francisco AL, Zurriaga O, García Blasco MJ, García Bazaga Mde L, Ramos Aceitero JM, Gil Paraíso A, Sánchez Casajús A, Unzue Gazteu JJ. Magaz Lago A. Informe de la situación de diálisis y trasplante en España, 2005. Nefrologia. 2008; 28: 151-158. PubMed
26. Herrera J. Enfermedad de Fabry en pacientes en hemodiálisis. Med Clin Monogr (Barc). 2010; 11: 33-34.
27. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010; 47: 217-222. Cross- Ref PubMed
28. Kosch M, Koch HG, Oliveira JP, Soares C, Bianco F, Breuning F, Rasmussen AK, Schaefer RM. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int. 2004; 66: 1279-1282. CrossRef PubMed
29. Herrera J, Vidau P. La Enfermedad de Fabry en pacientes en hemodiálisis: valoracion del tratamiento enzimático sustitutivo. Dial Traspl. 2011; 33: 71-74. doi:10.1016/j.dialis.2011.11.002.
30. Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, Silva FA, Tuna A, Rodrigues M, Ferreira C, Pinto AA, Leitão A, Gabriel JP, Calado S, Oliveira JP, Ferro JM; PORTuguese Young STROKE Investigators. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study - screening genetic conditions in Portuguese young stroke patients. Stroke. 2010; 41: 431-436. CrossRef PubMed
31. Morais P, Santos AL, Baudrier T, Mota AV, Oliveira JP, Azevedo F. Angiokeratomas of Fabry successfully treated with intense pulsed light. J Cosmet Laser Ther. 2008; 10: 218-222. CrossRef PubMed
32. Gal A. Molecular Genetics of Fabry Disease and Genotype-Phentype Correlation. In: Elstein D, Altarescu G, Beck M (eds). Fabry Disease. Springer; 2010. p. 3-19.
33. DeCaluwé GL, Bovee-Geurts PH, Rath P, Rothschild KJ, de Grip WJ. Effect of carboxyl mutations on functional properties of bovine rhodopsin. Biophys Chem. 1995; 56: 79-87. CrossRef PubMed.
34. Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litvak S, Nagle JW, Schiffmann R. Identification of fifteen novel mutations and genotype- phenotype relationship in Fabry disease. Clin Genet. 2001; 60: 46-51. CrossRef PubMed
35. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP; Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008; 93: 112-128. CrossRef PubMed
36. Mehta A, Ricci R, Widmer U, Dehout F, García de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004; 34: 236-242. CrossRef PubMed
37. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol. 2002; 13 (Suppl 2): S139-S143. PubMed
38. Vedder AC, Linthorst GE, Houge G, Groener JEM, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE. 2007; 2: e598 CrossRef PubMed
39. Pintos-Morell G, Lidove O, Mehta A. Management of Fabry disease with agalsidase treatment. Clin Med insights. Ther. 2010; 2: 953-963.
40. Ramaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther. 2011; 5: 155-173. CrossRef PubMed
41. Keating GM. Agalsidase alfa: a review of its use in the management of Fabry disease. BioDrugs. 2012; 26: 335-354. PubMed
42. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006; 21: 345-354. CrossRef PubMed
43. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006; 15: 330-333. PubMed
44. Barbey F, Lidove O, Schwarting A. Fabry nephropathy: 5 years of enzyme replacement therapy - a short review. Nephrol Dial Transplant. 2008; 1: 11-19.
45. Mignani R, Feriozzi S, Schaefer RM, Breunig F, Oliveira JP, Ruggenenti P, Sunder-Plassmann G. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol. 2010; 5: 379-385. CrossRef PubMed
46. Hughes DA, Barba Romero MA, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS - the Fabry Outcome Survey. Mol Genet Metab. 2011; 103: 207-214. CrossRef PubMed
47. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant. 2007; 22: 1920-1925. CrossRef PubMed
48. Martín de Francisco AL, Aguilera L, Fuster V. Enfermedad cardiovascular, enfermedad renal y otras enfermedades crónicas. Es necesaria una intervención más temprana en la enfermedad renal crónica. Nefrologia. 2009; 29: 6-9. PubMed